SCHEMBL16740845

SCHEMBL16740845

Cc1nc2cc(Cl)c(Cl)cc2n1-c1nc(N)nc(Nc2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 6/20 0.47
AGPAT2 O15120 1/20 0.43
APP P05067 1/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HSP90AA1 P07900 1/20 0.38
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
FFAR1 O14842 1/20 0.37
CYBB P04839 1/20 0.36
NOX5 Q96PH1 1/20 0.36
NOX3 Q9HBY0 1/20 0.36
NOX4 Q9NPH5 1/20 0.36
NOX1 Q9Y5S8 1/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
KCNH3 Q9ULD8 1/20 0.36
DHFR P00374 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740804 0.89 AGPAT2 (0.49) BMI1AGPAT2APPLMNAMAPT
SCHEMBL16748579 0.89 BMI1 (0.51) BMI1AGPAT2APPLMNAMAPT
SCHEMBL16748477 0.88 BMI1 (0.50) BMI1AGPAT2LMNAMAPTCTSS
SCHEMBL16748533 0.85 BMI1 (0.64) BMI1AGPAT2LMNAMAPTCTSS
SCHEMBL16748531 0.85 BMI1 (0.54) BMI1AGPAT2APPLMNAMAPT
SCHEMBL16748479 0.84 BMI1 (0.62) BMI1KCNH3
SCHEMBL16748451 0.82 AGPAT2 (0.42) BMI1AGPAT2APPLMNAMAPT
SCHEMBL16740869 0.80 PIK3CD (0.48) AGPAT2APPCYBBNOX5NOX3
SCHEMBL16740870 0.80 BMI1 (0.48) BMI1AGPAT2APPLMNAMAPT
SCHEMBL16748492 0.80 BMI1 (0.50) BMI1AGPAT2APPLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885AGPAT2 3973/4885APP 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.